Date: 2017-03-30
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: ADC Therapeutics (Switzerland)
Product: ADCT-502.
Action mechanism: antibody drug conjugate. ADCT-502 is an antibody drug conjugate (ADC) composed of an engineered version of trastuzumab, directed against human epidermal growth factor receptor 2 (HER2). The antibody is site-specifically conjugated to the PBD-based linker-drug tesirine. Once bound to the HER2 receptor on the cell surface, ADCT-502 is internalized into the cell where enzymes release the PBD-based warhead. HER2 is a well-established, clinically validated target expressed in a wide variety of solid tumors, including breast, gastric, esophageal, bladder and lung cancer.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: • On March 30, 2017, ADC Therapeutics announced that it will present a poster highlighting preclinical results from ADCT-502 at the American Association for Cancer Research (AACR) Annual Meeting 2017. Poster title is: "Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing Antibody Drug Conjugate (ADC) targeting HER2-expressing solid tumors"(Abstract #52). The preclinical data show superior in vivo anti-tumor activity of ADCT-502 compared to T-DM1 in various tumor xenografts with low HER2 levels and support the development of ADCT-502 not only in patients that have become resistant/refractory to T-DM1, but also in patients whose tumors express low levels of HER2, and are not eligible for treatment with T-DM1. ADC Therapeutics anticipates starting a Phase I clinical trial in patients with solid tumors during first half of 2017.
